« Return to News | Clinical Intelligence

Bert Spilker's Pharma Principles of The Week

Friday, January 19, 2007 09:57 AM

Posted by: Bert Spilker

  • Managing research scientists cannot be too heavy handed with the same control mechanisms in place that one uses for development of products.  Medical product development and marketing activities can be more tightly planned and controlled than that of discovery.
  • Good, fast, cheap.  Choose any two. You can rarely ever have all three.
    • If you want it good and fast, it won’t be cheap.
    • If you want it good and cheap, it won’t be fast.
    • If you want it fast and cheap, it won’t be good.
  • Good data in a few patients are a far better basis to make a decision on, than mediocre data in many patients. This principle is often ignored by those who collect a great deal of uncontrolled data rather than collecting less data from a well-controlled trial.

Bert Spilker, PhD, MD is an independent consultant who was most recently the Senior Vice President of Scientific and Regulatory Affairs for PhRMA. He is the founder of Bert Spilker & Associates (BS&A).

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.